Novartis’ CAR-T trials have disclosed three deaths tied to autoimmune risk questions, Reuters-style prompting scrutiny of the therapy’s safety profile. The developments reportedly follow concerns among researchers about whether CAR-T cell therapies could shift the autoimmune treatment paradigm while maintaining acceptable risk. The trial disclosures add a cautionary signal for developers aiming to broaden CAR-T into immune reset and autoimmune indications. Investors and clinicians are likely to recalibrate views on manufacturing controls, patient selection, and side effect monitoring strategies. The episode emphasizes that safety signals in early clinical disclosures can reshape development plans—especially in settings where off-target immune effects and autoimmune complications are central uncertainties.